TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing

SAVLI, HAKAN; Sertdemir, NİLÜFER; AYDIN, DUYGU; Dursun, Bilge; KURTAŞ, ÖMER; Reka, Seda; Sunnetci-Akkoyunlu, DENİZ; Eren-Keskin, SEDA; UYGUN, KAZIM; ÖZDEN, ERCAN; Isik, Ulas; ÇABUK, DEVRİM; Demir, Gulhan; Guzdolu, Eda; Gokbayrak, Merve; Aksu, MAKSUT; Canturk, NUH; Cine, NACİ

doi:10.1016/j.jbiotec.2019.05.005

TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing

Atıf İçin Kopyala

SAVLI H., Sertdemir N., AYDIN D., Dursun B., KURTAŞ Ö., Reka S., ...Daha Fazla

JOURNAL OF BIOTECHNOLOGY, cilt.300, ss.87-93, 2019 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 300
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.jbiotec.2019.05.005
Dergi Adı: JOURNAL OF BIOTECHNOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.87-93
Anahtar Kelimeler: Cell-Free DNA, Breast cancer, Lung cancer, TP53, EGFR, PIK3CA, CIRCULATING TUMOR-CELLS, NEVER-SMOKERS, MUTANT P53, MUTATIONS, ADENOCARCINOMA, CARCINOMA
Kocaeli Üniversitesi Adresli: Evet

Özet

Use of plasma cell-free DNA genomic testing, also know as liquid biopsy, reveals information for early detection and monitoring of solid tumors. Our study reports the analysis of 113 lung and 18 breast cancer patients using commercially available platforms. Lung and breast cancer panel hotspot regions on the genes were investigated. There was a significant increase in isolation efficiency with very fresh blood samples of at least 15 millilitres which were processed in minutes. TP53 gene variations were detected in both types of tumors. Additionally, associations were found for EGFR variations in lung tumors and PIK3CA variations in breast tumors. Mutation assessment of these three genes are recommended as useful biomarkers for predictive studies, to follow up tumor growth and for personalized treatment. Mutations observed in this study warrant further investigation for follow up studies and may justify expression studies. However, in our subsequent studies, we intensify our tumor profiling strategy with other methods. However in terms of true personalized medicine, future plans would include repeating these studies with ctDNA size analysis and methylation analysis of the non-coding region in the individual tumors.